Search

We explored associations between lifetime eating disorder (ED) diagnoses and behaviors and menstrual dysfunction using logistic regression models. Body mass index (BMI) fully explained differences in the odds of secondary amenorrhea (SA) across diagnoses. Women with dieting behaviors had borderline significantly higher odds of SA than those without after accounting for BMI. We suggest the presence of a strong association between BMI and SA and that dieting might represent a risk factor for SA regardless of BMI and ED diagnosis. [ABSTRACT FROM AUTHOR]

Efficient processing of absolute magnitude and relative order of numbers is key for arithmetic development. This longitudinal study tested 1) whether there is a developmental shift in the contribution of symbolic magnitude and order processing to arithmetic between Grades 1 and 2, and 2) whether the development of symbolic numerical abilities is characterized by reciprocal predictive relations. In two independent samples (UK: N = 195, Austria: N = 161), order processing did not predict early developmental change in arithmetic, but emerged as a predictor in Grade 2. Symbolic magnitude processing in Grade 1 predicted subsequent developmental change in arithmetic, but not later on. Moreover, we observed cross-lagged relations between symbolic magnitude and order processing. Our findings confirm that the contributions of symbolic magnitude and order processing to arithmetic development are interactive and change across the first years of schooling. This may be driven by a developmental shift from procedural strategies to retrieval of arithmetic facts. • Symbolic magnitude processing was a predictor of arithmetic development in Grade 1, but not in Grade 2. • Order processing did not predict developmental change in Grade 1, emerging as a unique predictor of arithmetic in Grade 2. • Cross-lagged predictive relations between symbolic magnitude and order processing across the entire study period. • Interactive and changing contributions of symbolic magnitude and order processing to arithmetic development. [ABSTRACT FROM AUTHOR]

Background: Venous thromboembolism (VTE, including deep vein thrombosis [DVT] and pulmonary embolism [PE]) has an annual incidence rate of 104–183 per 100,000 person-years. After a VTE episode, the two-year recurrence rate is about 17%. Consequently, effective and safe anticoagulation is paramount. Edoxaban is a direct oral anticoagulant (DOAC) approved VTE treatment. Current safety and efficacy data are derived from clinical trials, and information about treatment durations beyond 12 months are not available. Methods: ETNA-VTE-Europe is an 18-month prospective, single-arm, non-interventional, multinational post-authorisation safety study. Approximately 310 sites across eight European countries (Austria, Belgium, Germany, Ireland, Italy, the Netherlands, Switzerland and the United Kingdom) will participate in the study, with the intention to represent the regional distributions of centres, healthcare settings and specialties. An estimated cohort of 2700 patients will be recruited, the only enrolment criteria being acute symptomatic VTE, no participation in an interventional study, and treating physician decision to prescribe edoxaban independently from the registry. Data from patient medical records and/or telephone interviews will be collected at baseline, 1, 3, 6, 12 and 18 months. The primary objective is to evaluate the 18-month rate of symptomatic VTE recurrence in patients with VTE treated with edoxaban outside a clinical trial. The co-primary objective is to evaluate the real-world rates of bleeding and adverse drug reactions. Secondary outcomes include rates of other patient-relevant safety events, adherence to and discontinuation of edoxaban. Furthermore, 12-month ETNA-VTE-Europe data will be considered in the context of those for patients receiving different anticoagulants in the PREFER in VTE registry and Hokusai-VTE clinical trial. Conclusions: ETNA-VTE-Europe will allow the safety and effectiveness of edoxaban to be evaluated over an extended period in acute symptomatic VTE patients encountered in routine clinical practice. Findings will be informative for European practitioners prescribing edoxaban as part of real-world VTE treatment/prevention. Trial registration: ClinicalTrials.gov Identifier: NCT02943993. [ABSTRACT FROM AUTHOR]